Indeed, anti-TNF-α treatments alongside other inhibitory antibodies have transformed the pharmacological approach to chronic inflammatory diseases such as rheumatoid arthritis, psoriasis, and inflammatory bowel diseases, all being conditions with increased cardiovascular and cerebrovascular risk [36]. The gene discussed is TNF; the disease is inflammatory bowel disease.